15-Dec-15 Despite recording gains in recent years, India continues to lag several health indicators such as mortality rates and malnutrition. A paper in The Lancet identifies seven structural problems: 1. A weak primary healthcare; 2. Unequally distributed human resources; 3. Large unregulated private sector; 4. Low public spending; 5. Fragmented information systems; 6. Irrational drug use and spiralling cost; 7. Weak governance and accountability. [image: Hindustan Times]

11-Dec-15 India’s Ministry of Health & Family Welfare (MOHFW) and the Central Drugs Standard Control Organization (CDSCO) have met with medical device association representatives to discuss how the country can become a hub for device manufacturing and begin to align with global regulations. The discussion centered on increasing device exports and evaluating new guidance for the industry. [image: RAPS]

10-Dec-15 US-based healthcare IT firm eClinicalWorks will invest USD30 mn as part of its expansion plans for the digital healthcare market in India. The investment will focus on developing cloud-based technology infrastructure, the company said. eClinicalWorks has said tele-health capabilities allow patients to access their doctors via mobile phones and enable them to immediately address medical concerns. [image: Reuters]

07-Dec-15 Diabetes afflicts over 400 mn people. Many new technologies are being developed but those with the greatest impact will likely be low-cost solutions that can be applied in markets such as China, India, Brazil, Mexico and Indonesia. Low-cost programs are becoming increasingly possible, for example mClinica's patient management programs tailored for emerging markets, that use mobile messaging to encourage healthy behaviors. [image: Shutterstock]

01-Dec-15 At a recent India-Africa summit, Prime Minister Modi discussed working together to improve public health with 54 African heads of state. For India, the main goal is to increase pharmaceutical exports to Africa, while African ministers are keen to copy India’s success in developing drug manufacturing, both to secure their own supplies and to give their economies a fillip. [image: Reuters]